Drugs / BT063
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02554019 | Sep 2015 → Oct 2017 | systemic lupus erythematosus | Biotest | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT063 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02554019 ↗ |
| Route | Intravenous | “50 mg BT063 administered by intravenous (IV) infusion 8 times” NCT02554019 ↗ |